Effects of Endocrine Disruptors on the Gut Microbiota and Assessment of Their Impact on Colorectal Cancer Development (PERMICA)

Launched by POITIERS UNIVERSITY HOSPITAL · Jan 30, 2025

Keywords

ClinConnect Summary

The PERMICA trial is studying how certain chemicals called endocrine disruptors, which are often found in food and water, may affect the gut microbiota (the community of microorganisms living in our intestines) and their potential link to colorectal cancer. Colorectal cancer is a serious condition that affects many people, and this study aims to see if exposure to substances like parabens and phthalates is related to changes in gut bacteria and cancer development. The researchers will compare the gut microbiota of 100 patients with colorectal cancer to 100 patients without the disease to better understand these connections.

To participate in the trial, individuals must be scheduled for an endoscopy (a procedure to look inside the intestines) within 18 months and provide informed consent. Participants should not be receiving treatment for certain conditions or have had specific recent medical procedures. Throughout the study, which will last about nine years, participants will provide samples and information to help researchers gather valuable insights that could improve our understanding of colorectal cancer and its relationship with lifestyle factors. While individual benefits are not guaranteed, the findings could enhance our overall knowledge about colorectal cancer and potentially guide future preventive measures.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Scheduled endoscopy during the inclusion visit or within 18 months following this consultation.
• • Signed consent from the patient after clear and fair information about the study is provided.
• • Patient is free of guardianship, curatorship, or dependency.
• • Patient is covered by a social security system or through a third party.
• Exclusion Criteria:
• • Patients receiving treatment for chronic inflammatory bowel disease;
• • Patients with hereditary colorectal cancer;
• • Use of antibiotics, probiotics, or prebiotics within four weeks prior to stool sample collection;
• • Patients who have undergone neoadjuvant chemotherapy or radiotherapy;
• • Patients who have had previous surgical resection;
• • Patients under enhanced protection: minors, individuals deprived of liberty by judicial or administrative decision, individuals residing in healthcare or social institutions, and adults under legal protection;
• • Pregnant and/or breastfeeding women.
• Exclusion Criteria During Study Participation:
• * Patients presenting any of the following during their participation in the study will be excluded:
• • Use of antibiotics, probiotics, or prebiotics before stool collection (between inclusion and stool collection, which may occur within the month);
• • Endoscopy not performed within 18 months following inclusion;
• • Failure to send/receive stool samples